Valuation: Polaryx Therapeutics, Inc.

Market Cap 99.19M 85.14M 79.91M 72.98M 138M 9.46B 138M 946M 366M 4.77B 372M 364M 15.81B P/E 2026 *
-10.2x
P/E 2027 * -6.92x
Enterprise Value 99.19M 85.14M 79.91M 72.98M 138M 9.46B 138M 946M 366M 4.77B 372M 364M 15.81B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
30.08%
Yield 2026 *
-
Yield 2027 * -
1 day+0.75%
1 week-6.94%
Current month-12.99%
1 month+2.55%
3 months-22.09%
6 months-36.99%
1 week 1.85
Extreme 1.85
2.2
1 month 1.85
Extreme 1.85
2.68
Current year 1.85
Extreme 1.85
48.91
1 year 1.85
Extreme 1.85
48.91
3 years 1.85
Extreme 1.85
48.91
5 years 1.85
Extreme 1.85
48.91
10 years 1.85
Extreme 1.85
48.91
Manager TitleAgeSince
Chief Executive Officer 56 28/02/2023
Director of Finance/CFO 60 31/05/2024
Chief Tech/Sci/R&D Officer 59 31/01/2024
Director TitleAgeSince
Chairman 56 31/05/2021
Director/Board Member 60 31/07/2025
Director/Board Member - 28/01/2026
Date Insider Type Main position Quantity % Market Cap.
18/02/26 Buy

Chief Financial Officer

2,867 -
29/01/26 Other

Chief Financial Officer

225,358 -
29/01/26 Other

Chief Executive Officer

24,144,796 -
Change 5-day change 1-year change 3-year change Capi.($)
+0.75%-6.94% - - 99.19M
-1.01%+1.48%+1.66%+23.62% 51.65B
+0.03%-0.97%+470.30%+558.96% 45.31B
+0.69%+5.09%+39.53%+18.12% 42.7B
-0.32%-0.37%+21.54%+85.79% 42.79B
-2.27%-3.02%+14.22%+51.50% 32.87B
+0.78%+1.74%+31.87%+136.52% 17.14B
-0.80%-3.22% - - 16.61B
-1.70%+3.06%+11.11%+28.57% 15.01B
+0.07%+2.80%+82.11%+49.99% 14.21B
Average -0.36%+2.20%+84.04%+119.13% 27.84B
Weighted average by Cap. -0.45%+2.74%+100.70%+138.19%

Financials

2026 *2027 *
Net sales - -
Net income -9.16M -7.87M -7.38M -6.74M -12.73M -874M -12.79M -87.37M -33.86M -441M -34.41M -33.66M -1.46B -16.42M -14.1M -13.23M -12.09M -22.81M -1.57B -22.92M -157M -60.69M -790M -61.67M -60.33M -2.62B
Net Debt - -
Logo Polaryx Therapeutics, Inc.
Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs). Its drug candidate pipeline includes PLX-200 (gemfibrozil), PLX-300 (cinnamic acid), PLX-100, and PLX-400. PLX-200 (gemfibrozil), its advanced drug candidate, is an oral small molecule for the treatment of LSDs. PLX-200 is a repurposed drug that the Company is pursuing through a 505(b)(2) regulatory pathway and is designed to be administered through a novel and proprietary oral solution. PLX-300 (cinnamic acid) is a novel, oral small molecule therapy in IND-enabling studies for the treatment of LSDs. PLX-300 is an unsaturated carboxylic acid that occurs naturally in several plants as a deaminated product of phenylalanine. PLX-100 is a preclinical stage orally administrable combination therapy comprised of its PPARa agonist, PLX-200, and vitamin A, a RXRa agonist.
Employees
-
Date Price Change Volume
26/08/26 US$2.010 +1.01% 38,601
25/08/26 US$1.990 +6.42% 107,209
24/08/26 US$1.870 -9.66% 286,161
21/08/26 US$2.070 -3.27% 108,472
20/08/26 US$2.140 -0.93% 55,811
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.990USD
Average target price
7.500USD
Spread / Average Target
+276.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PLYX Stock